How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Targeted Contrast Agent Market
- By Contrast Agent Type: Iron Oxide Nanoparticles, Gadolinium-based Agents, Microbubbles, Gold Nanoparticles, Perfluorocarbon Nanodroplets
- By Imaging Modality: Magnetic Resonance Imaging (MRI), Ultrasound Imaging, Computed Tomography (CT), Positron Emission Tomography (PET), Optical Imaging
- By Target Application: Oncology, Cardiovascular Imaging, Neurological Disorders, Inflammatory Diseases, Infectious Diseases
- By Targeting Mechanism: Ligand-mediated Targeting, Antibody-based Targeting, Peptide-based Targeting, Aptamer-based Targeting, Magnetic Targeting
- By End User: Hospitals, Diagnostic Imaging Centers, Research Laboratories, Pharmaceutical and Biotechnology Companies
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Iron Oxide Nanoparticles leads By Contrast Agent Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 305 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.184 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.192 →
Full report · locked preview
Everything inside the Targeted Contrast Agent Market report
A complete, evidence-based study - 12 chapters and 128 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →GE Healthcare
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Bracco Imaging S.p.A.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Bayer AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Siemens Healthineers
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Lantheus Holdings Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Mallinckrodt Pharmaceuticals
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Invicro LLC
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →BioLegend Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Cytodiagnostics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Advanced Magnetics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Guerbet Group
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Sino Biological Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →NanoDiagnostic Technologies Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →ImaginAb Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Molecular Targeting Technologies
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Iron Oxide Nanoparticles46.1
- Gadolinium-based Agents8.3
- Microbubbles15.0
- Gold Nanoparticles21.9
- Perfluorocarbon Nanodroplets8.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- GE Healthcare14.2
- Bracco Imaging S.p.A.23.2
- Bayer AG12.9
- Siemens Healthineers4.3
- Lantheus Holdings Inc.7.0
- Mallinckrodt Pharmaceuticals10.5
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America30.9
- Europe23.7
- Asia Pacific20.8
- Latin America13.7
- Middle East and Africa11.0
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| GE Healthcare | 94 | 84 | 78 | 86 | 78 | 96 | 86 |
| Bracco Imaging S.p.A. | 90 | 84 | 83 | 79 | 71 | 68 | 79 |
| Bayer AG | 76 | 75 | 65 | 83 | 78 | 67 | 74 |
| Siemens Healthineers | 59 | 69 | 82 | 68 | 62 | 71 | 69 |
| Lantheus Holdings Inc. | 76 | 57 | 73 | 72 | 59 | 76 | 69 |
| Mallinckrodt Pharmaceuticals | 65 | 61 | 48 | 46 | 68 | 59 | 58 |
| Invicro LLC | 44 | 61 | 61 | 45 | 62 | 40 | 52 |
| BioLegend Inc. | 47 | 44 | 59 | 51 | 35 | 55 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- GE Healthcare
- Bracco Imaging S.p.A.
- Bayer AG
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| GE Healthcare | ✓ | ✓ | ◐ | ◐ | ◐ | ✓ |
| Bracco Imaging S.p.A. | ✓ | ◐ | ◐ | ◐ | ✓ | ◐ |
| Bayer AG | ◐ | ✓ | ◐ | ✓ | ◐ | ◐ |
| Siemens Healthineers | ◐ | − | ✓ | ◐ | ◐ | ✓ |
| Lantheus Holdings Inc. | ◐ | − | ✓ | ◐ | − | ◐ |
| Mallinckrodt Pharmaceuticals | ◐ | − | − | − | − | − |
| Invicro LLC | − | − | − | − | − | − |
| BioLegend Inc. | − | ◐ | ◐ | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Challenger3
Strong scale, closing on the leaders.
Contender1
Focused players with pockets of strength.
Niche2
Specialists in a single segment or region.
Go-to-market strategy
Land Contrast Agent Type in North America, then scale across Targeted Contrast Agent Market — a $480M beachhead inside a $6.44B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Iron Oxide Nanoparticles
Best fit — highest urgency & budget in Contrast Agent Type.
Gadolinium-based Agents
Strong fit — clear ROI and a fast path to value.
Microbubbles
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Contrast Agent Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Imaging Modality & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Target Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Contrast Agent Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Targeted Contrast Agent Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
Targeted Contrast Agent Market is a high-growth opportunity — $10.6B by 2033, compounding at 10.9%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.9% CAGR
Demand compounds through 2033, outpacing GDP across Contrast Agent Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Contrast Agent Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Imaging Modality optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Targeted Contrast Agent Market — a $1.13B market by 2033. Plan: grow share from 8.2% to 13.9%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.2% | 13.9% | Behind |
| Revenue | $96M | $157M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 32.1% | 39.8% | At risk |
| Customer retention | 86.1% | 94.0% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Contrast Agent Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Imaging Modality capability
A defensible second engine — invest in Imaging Modality to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Contrast Agent Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Imaging Modality
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $23M capacity & capability investment
- Greenlight bolt-on M&A in Imaging Modality
- Authorise North America expansion plan
- Fund R&D program for Contrast Agent Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAhead
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentBehind
Sales deck · value proposition
Win the Targeted Contrast Agent Market conversation — a $5.33B market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Contrast Agent Type
Goal Grow share in Contrast Agent Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Targeted Contrast Agent Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
Targeted Contrast Agent Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Targeted Drug Therapy Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportTargeted Protein Degraders Market
Market size, share, segmentation and regional forecast.
$755M market · 2025 base year
View reportTargeted Temperature Management for Post Cardiac Arrest Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportTargeted Temperature Management System Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportTargeted Therapeutics Market
Market size, share, segmentation and regional forecast.
$700M market · 2025 base year
View reportTargeting Pod Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportTariff Fractions Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportTaro Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportTarot Card Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportTarot Decks Market
Market size, share, segmentation and regional forecast.
$352M market · 2025 base year
View reportTarpaulin Sheet Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportTarps & Drop Cloths Market
Market size, share, segmentation and regional forecast.
$686M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy